Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

Journal of the American Academy of Dermatology

Volumn 77, Issue 1, 2017, Pages 88-97.e5

  Snast, Igor ^a   Atzmony, Lihi ^a   Braun, Marius ^a,b   Hodak, Emmilia ^a,b   Pavlovsky, Lev ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

biologic; HBcAg; hepatitis B virus; hepatitis C virus; psoriasis; reactivation; risk

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL PRODUCT; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; HEPATITIS B CORE ANTIBODY; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; SECUKINUMAB; USTEKINUMAB;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BIOLOGICAL THERAPY; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTION RISK; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; SEROLOGY; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VERY ELDERLY; VIRUS LOAD; VIRUS REACTIVATION; CHEMICALLY INDUCED; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS B; HEPATITIS C; PHYSIOLOGY; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL PRODUCTS; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 85019088919     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2017.01.037     Document Type: Article

References (85)

1. Menter, A., Gottlieb, A., Feldman, S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58 (2008), 826–850.
2. Garnock-Jones, K.P., Secukinumab: a review in moderate-to-severe plaque psoriasis. Am J Clin Dermatol 16 (2015), 323–330.
3. Leonardi, C.L., Powers, J.L., Matheson, R.T., et al., Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003), 2014–2022.
4. Bergstrom, L., Yocum, D.E., Ampel, N.M., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50 (2004), 1959–1966.
5. Balato, N., Di Costanzo, L., Ayala, F., et al. Psoriatic disease and tuberculosis nowadays. Clin Dev Immunol, 2012, 2012, 747204.
6. Kim, S.Y., Solomon, D.H., Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 6 (2010), 165–174.
7. Ryu, H.H., Lee, E.Y., Shin, K., et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol 31 (2012), 931–936.
8. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
9. Lok, A.S., Lai, C.L., Wu, P.C., et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92 (1987), 1839–1843.
10. Torres, H.A., Davila, M., Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 9 (2012), 156–166.
11. Pattullo, V., Hepatitis B reactivation in the setting of chemotherapy and immunosuppression-prevention is better than cure. World J Hepatol 7:7 (2015), 954–967.
12. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
13. Sanz-Bueno, J., Vanaclocha, F., García-Doval, I., et al., members of the BIOBADADERM group. Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database. Actas Dermosifiliogr 106 (2015), 477–482.
14. Navarro, R., Vilarrasa, E., Herranz, P., et al. Safety and effectiveness of ustekinumab and antitumor necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicenter study in a clinical setting. Br J Dermatol 168 (2013), 609–616.
15. Chiu, H.Y., Chen, C.H., Wu, M.S., et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 169 (2013), 1295–1303.
16. Fotiadou, C., Lazaridou, E., Ioannides, D., Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 25 (2011), 471–474.
17. Morisco, F., Guarino, M., La Bella, S., et al. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol, 14, 2014, 214.
18. Cassano, N., Mastrandrea, V., Principi, M., et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 25 (2011), 285–289.
19. Prignano, F., Ricceri, F., Pescitelli, L., et al. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 164 (2011), 645–647.
20. Cho, Y.T., Chen, C.H., Chiu, H.Y., Tsai, T.F., Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 39 (2012), 269–273.
21. Koskinas, J., Tampaki, M., Doumba, P.P., Rallis, E., Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol 168 (2013), 679–680.
22. Conde-Taboada, A., Muñoz, J.P., Muñoz, L.C., López-Bran, E., Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol 60 (2009), 1077–1080.
23. Nosotti, L., Francesconi, F., Izzi, S., et al. Safety of antitumour necrosis factor-α therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 162 (2010), 1408–1410.
24. Kouba, M., Rudolph, S.E., Hrdlicka, P., Zuber, M.A., Hepatitis-B reactivation during treatment with tumor necrosis factor-blocker adalimumab in a patient with psoriasis arthritis. [in German] Dtsch Med Wochenschr 137:1-2 (2012), 23–26.
25. Corpas, T.D., Puchades, A.M., Gavilá, A.Z., et al. Reactivation of hepatitis B after administration of anti-TNFα in a patient with psoriasis. Int J Clin Med 3 (2012), 143–144.
26. Salvi, M., Macaluso, L., Luci, C., et al. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases 4 (2016), 49–55.
27. Raymundo, A.R., Facin, A.P., Silva de Castro, C.C., Faria, A.R., Safety of ustekinumab in severe psoriasis with chronic hepatitis B. Indian J Dermatol Venereol Leprol 82 (2016), 326–328.
28. Notarnicola, A., Iannone, F., Lopalco, G., A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. Reumatismo 65 (2014), 298–301.
29. Abuchar, A., Vitiello, M., Kerdel, F.A., Psoriasis treated with ustekinumab in a patient with hepatitis C. Int J Dermatol 52 (2013), 381–382.
30. Babino, G., Esposito, M., Mazzotta, A., et al. Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis. Acta Derm Venereol 93 (2013), 373–374.
31. Prignano, F., Ricceri, F., Pescitelli, L., et al. Etanercept therapy in a hepatitis B virus (HBV)-positive psoriatic patient developing a monoclonal gammopathy of undetermined significance. Int J Dermatol 50 (2011), 999–1001.
32. Zanni, M., Missale, G., Santilli, D., Di Nuzzo, S., Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. Eur J Dermatol 21 (2011), 564–567.
33. Mederacke, I., Witte, T., Wedemeyer, H., Meyer-Olson, D., Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. Ann Rheum Dis 70 (2011), 1343–1344.
34. Gandhi, R.K., Pickup, T., Sheth, P.B., Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection?. Arch Dermatol 146 (2010), 1151–1152.
35. De Simone, C., Paradisi, A., Capizzi, R., et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 54 (2006), 1102–1104.
36. Magliocco, M.A., Gottlieb, A.B., Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004), 580–584.
37. Cecchi, R., Bartoli, L., Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J, 12, 2006, 4.
38. Rokhsar, C., Rabhan, N., Cohen, S.R., Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 54 (2006), 361–362.
39. Collazo, M.H., González, J.R., Torres, E.A., Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P R Health Sci J 27 (2008), 346–347.
40. Behnam, S.E., Hindiyeh, R., Fife, D.J., et al. Etanercept as prophylactic psoriatic therapy before interferon-and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol 35 (2010), 397–398.
41. Garavaglia, M.C., Altomare, G., Etanercept therapy in patients with psoriasis and concomitant HCV infection. Int J Immunopathol Pharmacol 23 (2010), 965–969.
42. Paradisi, A., Caldarola, G., Capizzi, R., et al. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol 62 (2010), 1067–1069.
43. Cassano, N., Vena, G.A., Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol 47 (2008), 980–981.
44. Alcaide, A.J., Barrera, M.V., Habicheyn, S., et al. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol 22 (2008), 1514–1516.
45. Thaçi, D., Pätzold, S., Kaufmann, R., Boehncke, W.H., Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol 152 (2005), 1048–1050.
46. Malara, G., Giunta, E., Lo Re, M., Ustekinumab treatment in psoriatic patient suffering from chronic hepatitis C. [poster abstract] J Am Acad Dermatol, 66, 2012, AB206.
47. Prignano, F., Zanieri, F., Milani, S., Lotti, T., Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. Dermatol Ther 22 (2009), 386–390.
48. Ventura, F., Gomes, J., Duarte Mda, L., et al. Efficacy and safety of etanercept in patients with psoriasis and hepatitis C. Eur J Dermatol 20 (2010), 808–809.
49. Aslanidis, S., Vassiliadis, T., Pyrpasopoulou, A., et al. Inhibition of TNFα does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26 (2007), 261–264.
50. Di Lernia, V., Guareschi, E., Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J, 16, 2010, 8.
51. Di Lernia, V., Zoboli, G., Ficarelli, E., Long-term management of HIV/hepatitis C virus associated psoriasis with etanercept. Indian J Dermatol Venereol Leprol, 79, 2013, 444.
52. Linardaki, G., Katsarou, O., Ioannidou, P., et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 34 (2007), 1353–1355.
53. Costa, L., Caso, F., Atteno, M., et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 33 (2014), 273–276.
54. Laurenti, R., Giovannangeli, F., Gubinelli, E., et al. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clin Dev Immunol, 2013, 2013, 410521.
55. Bartalesi, F., Salomoni, E., Cavallo, A., et al. Chronic hepatitis C virus hepatitis and psoriasis: no longer a contraindication to interferon use in the era of biological agents?. Scand J Infect Dis 45 (2013), 320–323.
56. Cavazzana, I., Ceribelli, A., Cattaneo, R., Franceschini, F., Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 8 (2008), 104–106.
57. Chiricozzi, A., Saraceno, R., Cannizzaro, M.V., et al. Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy. Dermatology 225 (2012), 333–337.
58. Gisondi, P., Prignano, F., Grossi, P., et al. Treatment of psoriasis with efalizumab in patients with hepatitis C viral infection: report of five cases. Dermatology 219 (2009), 158–161.
59. Esposito, M., Bianchi, L., Mazzotta, A., et al. Influence of etanercept on serum liver related tests and viral load values in patients with psoriasis and hepatitis C infection [poster abstract]. J Am Acad Dermatol, 56, 2007, AB174.
60. Di Nuzzo, S., Boccaletti, V., Fantini, C., et al. Are anti-TNF-α agents safe for treating psoriasis in hepatitis C virus patients with advanced liver disease? Case reports and review of the literature. Dermatology 232 (2016), 102–106.
61. Song, J.W., Chung, K.C., Observational studies: cohort and case-control studies. Plast Reconstr Surg 126 (2010), 2234–2242.
62. Mori, S., Fujiyama, S., Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 21 (2015), 10274–10289.
63. Takeshita, J., Gelfand, J.M., Li, P., et al. Psoriasis in the US Medicare population:pPrevalence, treatment, and factors associated with biologic use. J Invest Dermatol 135 (2015), 2955–2963.
64. Picardi, M., De Rosa, G., Selleri, C., et al. Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for hematological malignancies. Transplantation 82 (2006), 141–142.
65. Liang, R., Lau, G., Kwong, Y., Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17 (1999), 394–398.
66. Sera, T., Hiasa, Y., Michitaka, K., et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45 (2006), 721–724.
67. Pompili, M., Basso, M., Hohaus, S., et al. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Ann Hepatol 14 (2015), 168–174.
68. Sansone, S., Guarino, M., Castiglione, F., et al. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 20 (2014), 3516–3524.
69. Pérez-Alvarez, R., Díaz-Lagares, C., García-Hernández, F., et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90 (2011), 359–371.
70. Raimondo, G., Navarra, G., Mondello, S., et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 48 (2008), 743–746.
71. Sugauchi, F., Tanaka, Y., Kusumoto, S., et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 83 (2011), 412–418.
72. Raimondo, G., Allain, J.P., Brunetto, M.R., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49 (2008), 652–657.
73. Al-Mekhaizeem, K.A., Miriello, M., Sherker, A.H., The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. CMAJ 165 (2001), 1063–1064.
74. Davis, G.L., Hoofnagle, J.H., Waggoner, J.G., Spontaneous reactivation of hepatitis B virus infection. Gastroenterology 86 (1984), 230–235.
75. Yeo, W., Zee, B., Zhong, S., et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90 (2004), 1306–1311.
76. Yun, J., Kim, K.H., Kang, E.S., et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 104 (2011), 559–563.
77. Nast, A., Gisondi, P., Ormerod, A.D., et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris, update 2015, short version, EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 29 (2015), 2277–2294.
78. Zylberberg, H., Rimaniol, A.C., Pol, S., et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30 (1999), 185–191.
79. Pompili, M., Biolato, M., Miele, L., et al. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol:WJG 19 (2013), 7867–7873.
80. Pontisso, P., Bellati, G., Brunetto, M., et al. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity?. Hepatology 29 (1999), 585–589.
81. Hu, K.Q., Tong, M.J., The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29 (1999), 1311–1316.
82. European Association for Study of Liver, EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
83. Kalb, R.E., Fiorentino, D.F., Lebwohl, M.G., et al. Risk of serious infection with biologic and systemic treatment of psoriasis results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 151 (2015), 961–969.
84. Oliveira, G.J., Leles, C.R., Critical appraisal and positive outcome bias in case reports published in Brazilian dental journals. J Dent Educ 70 (2006), 869–874.
85. Nissen, T., Wynn, R., The clinical case report: a review of its merits and limitations. BMC Res Notes, 7, 2014, 264.